EUVIMEDEUVIMED entdecken
Open Access

The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence

Emeline Ragonnaud, Peter Holst

Therapeutic Advances in Vaccines · 2013

DOI: 10.1177/2051013613480446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Vaccines, 2013. Verfasst von Emeline Ragonnaud und 1 weiteren Autor:innen. Beteiligte Einrichtung: ISIM - Center for Medical Parasitology, Copenhagen, Denmark. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of vaccines that target tumor antigens in cancer has proven difficult. A major reason for this is that T cells specific for tumor self-antigens and neoantigens are eliminated or inactivated through mechanisms of tolerance. Antigen fusion strategies which increase the ability of vaccines to stimulate T cells that have escaped tolerance mechanisms, may have a particular potential as immunotherapies. This review highlights antigen fusion strategies that have been successful in stimulating the induction of T-cell immunity against cancer and counteracting tumor-associated tolerance. In preclinical studies, these strategies have shown to improve the potency of vectored vaccines through fusion of tumor antigen to proteins or protein domains that increase CD4+ T-cell help, CD8+ T-cell responses or both the CD4+ and CD8+ T-cell responses. However, in clinical trials such strategies seem to be less efficient when provided as a DNA vaccine. The first clinical trial using a viral vectored fusion-gene vaccine is expected to be tested as a partner in a heterologous prime-boost regimen directed against cervical cancer.

Schlagwörter

Stichwörter der Autor:innen

Antigen engineeringDNA vaccinebreaking of tolerancecancerimmunogenicitylow avidity T cellsviral vector vaccine

Autor:innen und Institutionen

  • ISIM - Center for Medical Parasitology, Copenhagen, Denmark.

Zitieren

APA

Ragonnaud, E., & Holst, P. (2013). The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence. Therapeutic Advances in Vaccines. https://doi.org/10.1177/2051013613480446

Vancouver

Ragonnaud E, Holst P. The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence. Therapeutic Advances in Vaccines. 2013. doi:10.1177/2051013613480446

BibTeX
@article{Ragonnaud2013,
  author = {Ragonnaud, Emeline and Holst, Peter},
  title = {The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence},
  journal = {Therapeutic Advances in Vaccines},
  year = {2013},
  doi = {10.1177/2051013613480446}
}
Kostenlos starten →